News

Global Markets Set for Growth: Why Emerging Economies Matter

Global Markets Set for Growth: Why Emerging Economies Matter

Goldman Sachs Predicts Bright Future for Global Equities

Goldman Sachs has delivered a positive outlook for long-term equity investors. The firm envisions steady gains for U.S. stocks in the coming decade while emphasizing a more robust growth potential in global markets.

S&P 500 Projections and Returns

In a recent note, Goldman Sachs forecasted the S&P 500 to reach 9,000 by 2030 and anticipates it hitting 11,100 by 2035. This projection, although optimistic, outlines a modest estimated annual return of 6.5% over the next ten years. This figure primarily stems from projected annual growth of 6% in earnings per share (EPS), coupled with dividends contributing 1.4% and a slight drag of 1% on valuations.

Historical Context of Returns

These anticipated returns sit below historical averages, with the 6.5% annualized return positioning itself at the 27th percentile compared to past performances since 1900. After adjusting for inflation, the firm's expected real return drops to about 4% per year, placing it in the 33rd percentile of actual historical returns.

Emerging Markets: The Real Growth Opportunity

Interestingly, the report highlights that emerging markets present an even more promising investment landscape, with projections of 10.9% annual returns in local currency and 12.8% in USD. This outlook nearly doubles the anticipated returns from the S&P 500.

Structural Factors Supporting Growth

Various structural factors are bolstering this optimistic forecast, including an average annual EPS growth of 8.7%, robust dividend yields of 2.9%, and enhancements in corporate governance and capital efficiency across several emerging markets, particularly in regions such as India, China, and South Korea.

Indications of Strong Growth in India

Among these markets, India stands out with expectations of 12.6% average annual earnings growth, attributed to its strong GDP performance and favorable demographic trends. Additionally, anticipated policy reforms are set to elevate dividend payouts and share buybacks throughout the sector.

Asia’s Contributions to Global Growth

The Asian markets, excluding Japan, are also expected to showcase impressive returns at around 10.3%, driven by 9% EPS growth and a 2.7% dividend yield despite some valuation compression. Japan, traditionally perceived as underperforming, is projected to reach annual returns of 8.2% backed by improving corporate governance.

Rethinking Investment Strategies

Integral to Goldman's outlook is the anticipation of a declining U.S. dollar, which is expected to depreciate steadily over the next decade. Historically, a weaker dollar has corresponded with superior performance in non-U.S. equities, presenting greater opportunities for investors with a diverse portfolio.

Implications of AI and Global Growth

The report also highlights the long-term ramifications of artificial intelligence (AI) as a global phenomenon, suggesting its benefits will extend well beyond U.S. tech giants. As such, Goldman Sachs encourages investors to branch out from U.S. markets, particularly towards emerging economies.

In summary, Goldman Sachs underscores a pivotal message: Although the S&P 500 retains its importance in global investment portfolios, a strategic shift towards emerging and Asian markets could yield significantly higher long-term returns. Investors are encouraged to consider this approach as growth, reform, and enhanced shareholder value appear likely to intensify in the coming years.

Frequently Asked Questions

What is Goldman Sachs’ prediction for the S&P 500?

Goldman Sachs predicts the S&P 500 will reach 9,000 by 2030 and 11,100 by 2035.

Which markets does Goldman Sachs expect to grow the fastest?

Goldman Sachs sees emerging markets, particularly in Asia, as having the highest growth potential, with returns expected to nearly double those of the S&P 500.

What factors are contributing to expected growth in emerging markets?

Key factors include robust EPS growth, favorable demographics, and policy reforms enhancing corporate governance.

How does the S&P 500's forecast compare historically?

Goldman's projected annualized return of 6.5% for the S&P 500 is below the historical average, falling within the lower percentiles of past performance.

What should investors consider for future opportunities?

Investors are advised to diversify into emerging markets, leveraging the projected growth driven by structural reforms and technological advancements.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 222

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 218

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 288

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 202

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 162

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 228

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 205

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 531

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading

Top 5 Most Recently Viewed Articles

Alto Neuroscience, Inc. Faces Class Action Lawsuit Risk

Updated Category News Views 181

Class Action Lawsuit Against Alto Neuroscience, Inc. Alto Neuroscience, Inc. (NYSE: ANRO) is currently facing a class action lawsuit filed by a national shareholder rights litigation firm. This lawsuit revolves around allegations of securities fraud, claiming the company made misleading statements regarding the efficacy of its product ALTO-100 in treating major depressive...

Continue Reading
Hyatt and Playa Hotels Explore Strategic Partnership Options

Updated Category News Views 218

Hyatt Engages in Exclusive Discussions with Playa Hotels Hyatt Hotels (NYSE: H) is currently in exclusive negotiations regarding a potential takeover of Playa Hotels & Resorts (NASDAQ: PLYA) N.V. This engagement marks a significant move for both companies as they explore various strategic options for the $1.2 billion resort operator. The announcement has generated...

Continue Reading
LingoAce Celebrated as Top Innovator in Global Education Market

Updated Category News Views 111

LingoAce Celebrated as Top Innovator in Global Education Market Pioneering Tech-driven, Personalized Learning for over 580,000 Learners Worldwide LingoAce, a prominent global EdTech company, has received recognition as a 2025 Forbes China Influential Brand in Education. This honor was presented during the inaugural 2025 Forbes China Educational Industry Summit,...

Continue Reading
Atea Pharmaceuticals Showcases Promising HCV Treatment Data

Updated Category News Views 138

Innovation in Hepatitis C Treatment by Atea Pharmaceuticals Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) has made a significant impact in the field of antiviral therapeutics through their ongoing research and development efforts. The company recently presented compelling data at The Liver Meeting 2024, highlighting the promising combination of bemnifosbuvir and ruzasvir for...

Continue Reading
NV5 Global Backs Major Coastal Mapping Initiative in New Zealand

Updated Category News Views 197

NV5 Global Secures $4 Million Coastal Mapping Contract NV5 Global, Inc. (NASDAQ: NVEE), a significant player in the professional engineering field, has recently secured a noteworthy contract with Toit? Te Whenua Land Information New Zealand (LINZ) for a $4 million coastal mapping project. This contract is an important milestone in NV5's effort to expand its international...

Continue Reading